Sigma-Aldrich has announced the launch of the Imprint DNA Modification kit.
This kit is based on Bisulfite DNA Modification technology licensed from Epigentek Group, a Brooklyn, New York based biotechnology company. The Imprint DNA Modification kit completely converts unmethylated cytosine to uracil in less than two hours and requires as little as 50 pg of input DNA. Once the deamination of cytosine to uracil is complete the resultant DNA product is suitable for downstream applications, including qPCR and bisulfite sequencing.
Bisulfite DNA conversion is a well-established technique that enables scientists to determine methylation patterns throughout the genome. The Imprint DNA Modification Kit offers researchers fast, sensitive and accurate results, enabling further downstream analyses of DNA methylation patterns and their impact on human health and development.
"Sigma-Aldrich is pleased to offer the best-in-class speed and sensitivity of the Imprint DNA Modification Kit, which enables users to rapidly research DNA methylation in various scientific applications," said Keith Jolliff, Director of Genomics and Functional Genomics at Sigma-Aldrich. "This complements an already robust product line to support the Epigenetic workflow, including DNA purification, qPCR, sequencing and post-reaction clean-up."
Adam Li, the Chief Scientific Officer at Epigentek, said, "We are very pleased with Sigma-Aldrich's decision to partner with Epigentek in the epigenetic field. This arrangement underscores Epigentek's position in the epigenetic arena, strengthens its strategy and portfolio, and is expected to benefit both companies' programs in developing new epigenetics technologies and products."